Literature DB >> 15157913

Therapeutic cloning applications for organ transplantation.

Chester J Koh1, Anthony Atala.   

Abstract

A severe shortage of donor organs available for transplantation in the United States leaves patients suffering from diseased and injured organs with few treatment options. Scientists in the field of tissue engineering apply the principles of cell transplantation, material science, and engineering to construct biological substitutes that will restore and maintain normal function in diseased and injured tissues. Therapeutic cloning, where the nucleus from a donor cell is transferred into an enucleated oocyte in order to extract pluripotent embryonic stem cells, offers a potentially limitless source of cells for tissue engineering applications. The present chapter reviews recent advances that have occurred in therapeutic cloning and tissue engineering and describes applications of these new technologies that may offer novel therapies for patients with end-stage organ failure. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Year:  2004        PMID: 15157913     DOI: 10.1016/j.trim.2003.12.006

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  3 in total

Review 1.  Stem cell technology for the treatment of acute and chronic renal failure.

Authors:  Christopher J Pino; H David Humes
Journal:  Transl Res       Date:  2010-07-30       Impact factor: 7.012

Review 2.  Injectable cardiac tissue engineering for the treatment of myocardial infarction.

Authors:  Haibin Wang; Jin Zhou; Zhiqiang Liu; Changyong Wang
Journal:  J Cell Mol Med       Date:  2010-02-27       Impact factor: 5.310

3.  Engineered heart tissue graft derived from somatic cell nuclear transferred embryonic stem cells improve myocardial performance in infarcted rat heart.

Authors:  Shuanghong Lü; Ying Li; Shaorong Gao; Sheng Liu; Haibin Wang; Wenjun He; Jin Zhou; Zhiqiang Liu; Ye Zhang; Qiuxia Lin; Cumi Duan; Xiangzhong Jerry Yang; Changyong Wang
Journal:  J Cell Mol Med       Date:  2010-12       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.